Sort   by:  
 Page size 
UnknownPost-acute COVID-19 outcomes including participant-reported long COVID: amubarvimab/romlusevimab versus placebo in the ACTIV-2 trial.
Not available
S-EPMC11381616 | biostudies-literature
UnknownSafety and Efficacy of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies Amubarvimab Plus Romlusevimab in Nonhospitalized Patients With COVID-19.
Not available
S-EPMC10150320 | biostudies-literature
UnknownDevelopment and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study.
Not available
S-EPMC4380415 | biostudies-literature
UnknownGlobal burden of 292 causes of death in 204 countries and territories and 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023.
Not available
S-EPMC12535838 | biostudies-literature
Sort   by:  
 Page size